Investigational drug · Phase 2
JNJ-64042056
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alzheimer Disease.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "JNJ-64042056"
First trial start
2024
Jul 22, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JNJ-64042056", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alzheimer Disease
Approved drugs for the same conditions: Alzheimer's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "JNJ-64042056" as an intervention, largest first.
- A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's DiseaseActive, not recruiting
Janssen Pharmaceutica N.V., BelgiumJohnson & Johnson (Janssen) (JNJ)
NCT06544616 · 55 participants · Start Jul 22, 2024 · Primary completion Dec 22, 2026
Drug: JNJ-64042056; Placebo · For: Alzheimer Disease
Sites: Phoenix, Arizona; Irvine, California; Murrieta, California · 90 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Alzheimer Disease
- KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials
Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder
- ITI-1284JNJ-99245354Phase 36 trials
Intra-Cellular Therapies, Inc. · Generalized Anxiety Disorder, Agitation Associated With Alzheimer's Dementia, Psychotic Disorders
- AXS-05dextromethorphan-bupropionPhase 33 trials
Axsome Therapeutics, Inc. · Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Smoking Cessation
- MasitinibAB1010Phase 33 trials
AB Science · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease
- SPG302TazbentetolPhase 33 trials
Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis
- Combined metabolic activatorsPhase 32 trials
ScandiBio Therapeutics AB · Alzheimer Disease, Gout Disease
- DMB-IINN: Latrepirdine, DimebonPhase 32 trials
Bigespas LTD · Alzheimer Type Dementia, Alzheimer Disease, Dementia of Alzheimer Type
- AR1001Phase 31 trial
AriBio Co., Ltd. · Alzheimer Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Johnson & Johnson (Janssen).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.